The IPO market in 2017 was one of the stronger ones we’ve seen in recent years, and Massachusetts led the way. Although the number of IPOs nationally is a bit lower than in 2016, they have raised significantly more money.
- 10 IPOs in 2017 from MA headquartered companies: That accounts for nearly half (48%) of all US-based biotech IPOs. That’s up from 31% of the US market in 2016.
- Additionally, those MA headquartered IPOs accounted for over half of all funds (52%) raised in 2017 (up from 24% in 2016).
- The average amount raised by the MA headquartered companies was $100 million in 2017 – higher than the national average of $91 million, which was also the highest it’s been in the past four years.
Massachusetts' disproportionate share of IPOs/funding is largely a reflection of the innovation happening here – gene and cell therapies, breakthrough treatments for rare diseases and the ongoing partnership between industry, academia and government.
Don't miss MassBio's #MAMonthlyFacts!